Latest News

Explore our latest corporate news, events and press releases.

Larka Advises Partners Group On Its Acquisition Of FairJourney Biologics

3 July 2024 - Larka is pleased to announce it performed the Commercial Due Diligence for Partners Group—supporting its acquisition of FairJourney Biologics, a leading antibody discovery Contract Research Organization (CRO).

Merger & Acquisition

Larka Advises Motion Equity On Its Acquisition Of Banook

3 November 2023 - Larka is delighted to announce it acted as the buy-side Commercial Due Diligence advisor for Motion Equity Partners—supporting its acquisition of Banook, a leading French Central Service Provider.

Merger & Acquisition

Larka Performs 4 Sourcing Processes for Global BioPharma Clients.

23 October 2023 - Leveraging Lensource®, Larka enabled the identification and selection of CRO, CDMO and CMO partners for 4 major Biotech & Pharma clients, including...

Tech Ops & Outsourcing

CMO Sourcing Process for Juvisé Pharmaceuticals

15 May 2023 - Juvisé Pharmaceuticals leveraged Larka’s Lensource® solution for the identification, assessment and selection of a Contract Manufacturing Organisation (CMO) partner to supply one of its commercial products.

Tech Ops & Outsourcing

Larka Advises Biose Industrie, Acquired by L-GAM & the French State

17 March 2023 - Larka is delighted to announce it acted as the sell-side Vendor Commercial Due Diligence provider to support the sale process of Biose Industrie—a world-leading Contract Development and Manufacturing Organisation (CDMO)—acquired by L-GAM & the French State.

Merger & Acquisition

Larka Advises Apax Partners On Its Acquisition Of Porsolt

8 March 2023 - Larka is delighted to announce it acted as the buy-side Commercial Due Diligence advisor for Apax Partners, supporting its acquisition of Porsolt, a leading French Contract Research Organization (CRO).

Merger & Acquisition

Larka Supports Albumedix' Sale Process, Acquired by Sartorius

26 October 2022 - Larka is delighted to announce it acted as the sell-side Vendor Commercial Due Diligence provider to support the sale process of Albumedix – a leading recombinant albumin-based solution provider based in Nottingham, UK – acquired by the Sartorius Group.

Merger & Acquisition

Larka Advises Keensight on CRO Axxam Acquisition

1 September 2022 - Larka is delighted to announce it acted as the buy-side Commercial Due Diligence provider to support Keensight Capital on its acquisition of a majority stake in Axxam, a global-leading Contract Research Organization (CRO) based in Italy.

Merger & Acquisition

Larka Advises Cathay on its Investment in CRO Transcure

31 August 2022 - Larka is thrilled to announce it performed the Commercial Due Diligence to support Cathay Capital’s investment in TransCure bioServices, a global-leading Contract Research Organization (CRO) based in France.

Merger & Acquisition

Larka Advises Merieux Equity Partners on its investment in Janvier Labs

26 July 2022 - Larka provides Merieux Equity Partners with a Commercial Due Diligence to support its investment in French BioPharma company Janvier Labs.

Merger & Acquisition

Larka Advises Elyan on CRO Oncodesign Acquisition Process

11 July 2022 - Larka provides Elyan Partners with a Commercial Due Diligence to support the acquisition of CRO services Business Unit of Oncodesign, a leading French BioPharma company.

Merger & Acquisition

Larka Advises Gimv on CDMO BioConnection Investment Deal

24 May 2022 - Larka provides Gimv with a Technical Due Diligence and Operational Due Diligence to support its investment in leading Dutch bio-CDMO BioConnection.

Merger & Acquisition

Interview with: Yana Marmann

25 April 2022 - Fresh out of college and hired amid the COVID-19 pandemic, Yana saw in Larka an opportunity to shape a career within the BioPharma industry while evolving in a fast-paced and exciting environment.

Our People

Vendor Due Diligence for Afinum and SHS | evitria

27 July 2021 - Larka is very pleased to announce that it’s M&A Unit performed the Vendor Commercial Due-Diligence to support Afinum’s exit process of evitria, a global leading service provider specialized in transient antibody expression.

Merger & Acquisition

Commercial Due Diligence for Keensight Capital | Symeres

7 June 2021 - Larka is very proud to announce that it performed the Commercial-Due-Diligence for Keensight Capital on its acquisition of Symeres.

Merger & Acquisition

Commercial Due Diligence for Clean Biologics & Archimed | Biodextris

11 May 2021 - Larka is pleased to announce that it performed the Commercial Due-Diligence for Clean Biologics group – backed by Archimed - on their acquisition of Biodextris.

Merger & Acquisition

Olivier Dumortier PhD Appointed as Business Development Manager

12 April 2021 - Prior to joining Larka’s Analysts team two years ago, Olivier did a PhD thesis in Belgium - exploring numerous models of metabolic diseases - then worked on non-coding RNA and regulation of cell metabolism and physiology in Canada and France for over a decade.

Our People

Maxime Clarhaut Appointed as Associate

8 April 2021 - Maxime has been working with Larka’s Analyst team for over two years now and keeps proving that dedication, combined with passion for Biotech and Pharma industry, lead to great achievements and value creation for our clients.

Our People

Lucas Leray joins Larka as Digital Marketing Manager

11 February 2021 - Lucas will be a valuable asset for our Marketing & Sales Business Unit, as he brings strong expertise in both Research Marketing and Digital Marketing, particularly cruci

Our People